Gilead Launches Two Phase 2 Trials of Denikitug in HER2-Negative GI Cancers and MSS Colorectal Cancer
Key Insights
Gilead Sciences has initiated two separate Phase 2 trials evaluating denikitug (GS-1811) in difficult-to-treat gastrointestinal cancers, with both studies currently recruiting participants.
One trial targets HER2 (search)-negative, unresectable or metastatic gastric, GEJ, and esophageal adenocarcinomas, testing denikitug alone or combined with nivolumab or ramucirumab plus paclitaxel.
The second trial focuses on advanced microsatellite stable (MSS) colorectal cancer, evaluating denikitug monotherapy and combinations with nivolumab or trifluridine-tipiracil (search) plus bevacizumab.
Gilead Sciences is expanding its oncology footprint with two new Phase 2 clinical trials investigating denikitug (GS-1811), an investigational antibody-based therapy administered via intravenous infusion, across two challenging gastrointestinal cancer indications. Both studies are currently recruiting and represent a strategic push into solid tumors beyond the company's established antiviral and cell therapy franchises.
Denikitug in HER2 (search)-Negative Upper GI Cancers
The first study, titled "A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy," targets adults with HER2 (search)-negative, unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinomas. Gilead first submitted the study on April 17, 2026, with the most recent update posted on July 9, 2026, signaling active study management.
The trial employs a randomized, parallel-design structure without blinding, meaning both physicians and patients are aware of the assigned treatment regimen. Patients are randomized to receive denikitug alone or in combination with either the immunotherapy nivolumab or the chemotherapy doublet of ramucirumab plus paclitaxel. The core objective is to assess tumor response and survival outcomes in a patient population that currently faces limited therapeutic options.
Primary and final completion dates have not yet been reported, and fuller details are available on ClinicalTrials.gov under identifier NCT07546812.
Denikitug in MSS Colorectal Cancer
The second study, "A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)," began enrollment on April 7, 2026. The latest update was filed on June 10, 2026, indicating that recruitment and protocol details remain current.
This trial evaluates denikitug both as monotherapy and in combination with nivolumab, as well as with a chemotherapy backbone of trifluridine-tipiracil (search) plus bevacizumab. The study targets patients with advanced MSS colorectal cancer, a molecular subtype known for limited responsiveness to immunotherapy and poor outcomes with standard approaches.
Like the upper GI trial, this study uses an interventional, randomized, parallel design without blinding, with the primary goal of measuring treatment benefit through tumor response.
Strategic Implications
These two studies mark a concerted effort by Gilead to build a presence in the competitive gastrointestinal oncology space. Positive efficacy signals could support a higher long-term growth narrative and help narrow the gap with oncology leaders such as Merck and Bristol Myers Squibb. Conversely, weak data could dampen sentiment regarding Gilead's ability to compete in crowded GI cancer markets.
Both trials remain ongoing with active recruiting status. Investors and clinicians alike will be watching for future data readouts and regulatory updates as the studies progress toward their primary and final completion milestones.